$3.00
14.50% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
NL0010872420
Symbol
AFMD
Sector
Industry

Affimed N.V. Stock price

$3.00
-0.33 9.77% 1M
-1.19 28.40% 6M
-3.25 52.00% YTD
-1.50 33.33% 1Y
-67.70 95.76% 3Y
-21.70 87.85% 5Y
-63.00 95.45% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.38 14.50%
ISIN
NL0010872420
Symbol
AFMD
Sector
Industry

Key metrics

Market capitalization $45.68m
Enterprise Value $33.16m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 34.91
P/S ratio (TTM) P/S ratio 48.08
P/B ratio (TTM) P/B ratio 2.56
Revenue growth (TTM) Revenue growth -95.23%
Revenue (TTM) Revenue $950.00k
EBIT (operating result TTM) EBIT $-80.15m
Free Cash Flow (TTM) Free Cash Flow $-83.38m
Cash position $26.90m
EPS (TTM) EPS $-3.64
P/E forward negative
P/S forward 29.92
EV/Sales forward 21.72
Short interest 6.66%
Show more

Is Affimed N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Affimed N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Affimed N.V. forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Affimed N.V. forecast:

Buy
83%
Hold
17%

Financial data from Affimed N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.95 0.95
95% 95%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 13 13
41% 41%
1,384%
- Research and Development Expense 61 61
48% 48%
6,372%
-76 -76
38% 38%
-8,046%
- Depreciation and Amortization 3.71 3.71
14% 14%
391%
EBIT (Operating Income) EBIT -80 -80
36% 36%
-8,437%
Net Profit -76 -76
40% 40%
-7,979%

In millions USD.

Don't miss a Thing! We will send you all news about Affimed N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Affimed N.V. Stock News

Neutral
Seeking Alpha
12 days ago
Affimed N.V. (NASDAQ:AFMD ) Q3 2024 Earnings Call Transcript November 14, 2024 8:30 AM ET Company Participants Alex Fudukidis - Head of Investor Relations & Director of Investor Relations Shawn Leland - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Michael Wolf - Head of Finance & Administration Conference Call Participants Li Watsek - Cantor Daina Graybosch - Leerink Partne...
Neutral
GlobeNewsWire
12 days ago
MANNHEIM, Germany, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the quarter ended September 30, 2024.
Neutral
GlobeNewsWire
20 days ago
MANNHEIM, Germany, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2024 results and corporate update on Thursday, November 14, 2024. The Company will host a conference call at 8:30 a.m. EST / 14:30 CET.
More Affimed N.V. News

Company Profile

Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Head office Netherlands
CEO Shawn Leland
Employees 78
Founded 2000
Website www.affimed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today